SCHEMBL17154385

SCHEMBL17154385

CC(=O)Nc1ccc(Nc2c3ccc([N+](=O)[O-])cc3nc3cc([N+](=O)[O-])ccc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.60
MAPT P10636 5/20 0.60
KDM4E B2RXH2 3/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
LMNA P02545 2/20 0.60
POLB P06746 2/20 0.60
KDM1A O60341 1/20 0.60
MITF O75030 1/20 0.60
RAD52 P43351 1/20 0.60
RECQL P46063 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
MEN1 O00255 3/20 0.56
GLA P06280 2/20 0.56
MAPK1 P28482 1/20 0.56
HTT P42858 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
GAA P10253 3/20 0.53
ALDH1A1 P00352 2/20 0.50
ACHE P22303 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17154406 0.85 KMT2A (0.54) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL17154369 0.84 KDM4E (0.53) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL4155709 0.82 KMT2A (0.54) KMT2AMAPTKDM4ESMN1; SMN2LMNA
SCHEMBL4164355 0.82 SMN1; SMN2 (0.53) KMT2AMAPTKDM4ESMN1; SMN2LMNA
SCHEMBL17154448 0.82 KMT2A (0.62) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL17154423 0.80 KDM1A (0.60) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL17154412 0.78 KMT2A (0.57) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL17154366 0.78 KMT2A (0.60) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL18407158 0.77 KMT2A (0.53) KMT2AMAPTKDM4ESMN1; SMN2NPSR1
SCHEMBL17154392 0.77 KMT2A (0.74) KMT2AMAPTKDM4ESMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10183912-B2 HDMX inhibitors and their use for cancer treatment MiRx Pharmaceuticals, LLC (US) 2019-01-22 US disclosed
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MIRX PHARMACEUTICALS LLC (US) 2017-01-26 US disclosed
WO-2015153535-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT MiRx Pharmaceuticals, LLC (US) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022166-A1 NOVEL HDMX INHIBITORS AND THEIR USE FOR CANCER TREATMENT TP53, DDX3X, API5 KMT2A 1544/4885MAPT 2621/4885KDM4E 809/4885
US-10183912-B2 HDMX inhibitors and their use for cancer treatment TP53, MDM4, MDM2 KMT2A 1514/4885MAPT 2632/4885KDM4E 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.